Cargando…
A Novel Six Metastasis-Related Prognostic Gene Signature for Patients With Osteosarcoma
Osteosarcoma is the most common malignant bone tumor, and although there has been significant progress in its management, metastases often herald incurable disease. Here we defined genes differentially expressed between primary and metastatic osteosarcoma as metastasis-related genes (MRGs) and used...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343004/ https://www.ncbi.nlm.nih.gov/pubmed/34368151 http://dx.doi.org/10.3389/fcell.2021.699212 |
_version_ | 1783734184973434880 |
---|---|
author | Zheng, Di Xia, Kezhou Yu, Ling Gong, Changtian Shi, Yubo Li, Wei Qiu, Yonglong Yang, Jian Guo, Weichun |
author_facet | Zheng, Di Xia, Kezhou Yu, Ling Gong, Changtian Shi, Yubo Li, Wei Qiu, Yonglong Yang, Jian Guo, Weichun |
author_sort | Zheng, Di |
collection | PubMed |
description | Osteosarcoma is the most common malignant bone tumor, and although there has been significant progress in its management, metastases often herald incurable disease. Here we defined genes differentially expressed between primary and metastatic osteosarcoma as metastasis-related genes (MRGs) and used them to construct a novel six-MRG prognostic signature for overall survival of patients with osteosarcoma. Validation in internal and external datasets confirmed satisfactory accuracy and generalizability of the prognostic model, and a nomogram based on the signature and clinical variables was constructed to aid clinical decision-making. Of the six MRGs, FHIT is a well-documented tumor suppressor gene that is poorly defined in osteosarcoma. Consistent with tumor suppressor function, FHIT was downregulated in osteosarcoma cells and human osteosarcoma samples. FHIT overexpression inhibited osteosarcoma proliferation, migration, and invasion both in vitro and in vivo. Mechanistically, FHIT overexpression upregulate the epithelial marker E-cadherin while repressing the mesenchymal markers N-cadherin and vimentin. Our six-MRG signature represents a novel and clinically useful prognostic biomarker for patients with osteosarcoma, and FHIT might represent a therapeutic target by reversing epithelial to mesenchymal transition. |
format | Online Article Text |
id | pubmed-8343004 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83430042021-08-07 A Novel Six Metastasis-Related Prognostic Gene Signature for Patients With Osteosarcoma Zheng, Di Xia, Kezhou Yu, Ling Gong, Changtian Shi, Yubo Li, Wei Qiu, Yonglong Yang, Jian Guo, Weichun Front Cell Dev Biol Cell and Developmental Biology Osteosarcoma is the most common malignant bone tumor, and although there has been significant progress in its management, metastases often herald incurable disease. Here we defined genes differentially expressed between primary and metastatic osteosarcoma as metastasis-related genes (MRGs) and used them to construct a novel six-MRG prognostic signature for overall survival of patients with osteosarcoma. Validation in internal and external datasets confirmed satisfactory accuracy and generalizability of the prognostic model, and a nomogram based on the signature and clinical variables was constructed to aid clinical decision-making. Of the six MRGs, FHIT is a well-documented tumor suppressor gene that is poorly defined in osteosarcoma. Consistent with tumor suppressor function, FHIT was downregulated in osteosarcoma cells and human osteosarcoma samples. FHIT overexpression inhibited osteosarcoma proliferation, migration, and invasion both in vitro and in vivo. Mechanistically, FHIT overexpression upregulate the epithelial marker E-cadherin while repressing the mesenchymal markers N-cadherin and vimentin. Our six-MRG signature represents a novel and clinically useful prognostic biomarker for patients with osteosarcoma, and FHIT might represent a therapeutic target by reversing epithelial to mesenchymal transition. Frontiers Media S.A. 2021-07-23 /pmc/articles/PMC8343004/ /pubmed/34368151 http://dx.doi.org/10.3389/fcell.2021.699212 Text en Copyright © 2021 Zheng, Xia, Yu, Gong, Shi, Li, Qiu, Yang and Guo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Zheng, Di Xia, Kezhou Yu, Ling Gong, Changtian Shi, Yubo Li, Wei Qiu, Yonglong Yang, Jian Guo, Weichun A Novel Six Metastasis-Related Prognostic Gene Signature for Patients With Osteosarcoma |
title | A Novel Six Metastasis-Related Prognostic Gene Signature for Patients With Osteosarcoma |
title_full | A Novel Six Metastasis-Related Prognostic Gene Signature for Patients With Osteosarcoma |
title_fullStr | A Novel Six Metastasis-Related Prognostic Gene Signature for Patients With Osteosarcoma |
title_full_unstemmed | A Novel Six Metastasis-Related Prognostic Gene Signature for Patients With Osteosarcoma |
title_short | A Novel Six Metastasis-Related Prognostic Gene Signature for Patients With Osteosarcoma |
title_sort | novel six metastasis-related prognostic gene signature for patients with osteosarcoma |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343004/ https://www.ncbi.nlm.nih.gov/pubmed/34368151 http://dx.doi.org/10.3389/fcell.2021.699212 |
work_keys_str_mv | AT zhengdi anovelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma AT xiakezhou anovelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma AT yuling anovelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma AT gongchangtian anovelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma AT shiyubo anovelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma AT liwei anovelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma AT qiuyonglong anovelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma AT yangjian anovelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma AT guoweichun anovelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma AT zhengdi novelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma AT xiakezhou novelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma AT yuling novelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma AT gongchangtian novelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma AT shiyubo novelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma AT liwei novelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma AT qiuyonglong novelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma AT yangjian novelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma AT guoweichun novelsixmetastasisrelatedprognosticgenesignatureforpatientswithosteosarcoma |